FGF21 and diabetic kidney disease: The peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate (FF), known for its efficacy in DKD, has been shown to prevent DKD development by mediating NRF2 pathway activation through FGF21 (63).